151 related articles for article (PubMed ID: 25882220)
1. Doxorubicin Action on Mitochondria: Relevance to Osteosarcoma Therapy?
Armstrong J; Dass CR
Curr Drug Targets; 2018; 19(5):432-438. PubMed ID: 25882220
[TBL] [Abstract][Full Text] [Related]
2. The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction.
Dolinsky VW
Biol Chem; 2017 Aug; 398(9):955-974. PubMed ID: 28253192
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway.
Danz ED; Skramsted J; Henry N; Bennett JA; Keller RS
Free Radic Biol Med; 2009 Jun; 46(12):1589-97. PubMed ID: 19303434
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.
Wallace KB; Sardão VA; Oliveira PJ
Circ Res; 2020 Mar; 126(7):926-941. PubMed ID: 32213135
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells.
Tacar O; Indumathy S; Tan ML; Baindur-Hudson S; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2015 Feb; 67(2):231-43. PubMed ID: 25208656
[TBL] [Abstract][Full Text] [Related]
6. Peripartum heart failure in a patient treated previously with doxorubicin.
Davis LE; Brown CE
Obstet Gynecol; 1988 Mar; 71(3 Pt 2):506-8. PubMed ID: 3162299
[TBL] [Abstract][Full Text] [Related]
7. Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.
Pillai VB; Kanwal A; Fang YH; Sharp WW; Samant S; Arbiser J; Gupta MP
Oncotarget; 2017 May; 8(21):34082-34098. PubMed ID: 28423723
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress induction by narasin augments doxorubicin's efficacy in osteosarcoma.
Han Z; Yang J; Wang P; Bian F; Jia J
BMC Pharmacol Toxicol; 2023 Oct; 24(1):56. PubMed ID: 37864240
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
Pereira GC; Silva AM; Diogo CV; Carvalho FS; Monteiro P; Oliveira PJ
Curr Pharm Des; 2011; 17(20):2113-29. PubMed ID: 21718248
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells.
Kluza J; Marchetti P; Gallego MA; Lancel S; Fournier C; Loyens A; Beauvillain JC; Bailly C
Oncogene; 2004 Sep; 23(42):7018-30. PubMed ID: 15273722
[TBL] [Abstract][Full Text] [Related]
11. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of the metabolic modulator Metformin on osteosarcoma cancer stem-like cells.
Paiva-Oliveira DI; Martins-Neves SR; Abrunhosa AJ; Fontes-Ribeiro C; Gomes CMF
Cancer Chemother Pharmacol; 2018 Jan; 81(1):49-63. PubMed ID: 29086064
[TBL] [Abstract][Full Text] [Related]
13. A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity.
de Oliveira BL; Niederer S
PLoS Comput Biol; 2016 Nov; 12(11):e1005214. PubMed ID: 27870850
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel toxicophore in anti-cancer chemotherapeutics that targets mitochondrial respiratory complex I.
Stephenson ZA; Harvey RF; Pryde KR; Mistry S; Hardy RE; Serreli R; Chung I; Allen TE; Stoneley M; MacFarlane M; Fischer PM; Hirst J; Kellam B; Willis AE
Elife; 2020 May; 9():. PubMed ID: 32432547
[TBL] [Abstract][Full Text] [Related]
15. Mitochondria-specific nano-emulsified therapy for myocardial protection against doxorubicin-induced cardiotoxicity.
Faulk A; Weissig V; Elbayoumi T
Methods Mol Biol; 2013; 991():99-112. PubMed ID: 23546663
[TBL] [Abstract][Full Text] [Related]
16. Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
Doroshow JH
Cancer Res; 1983 Feb; 43(2):460-72. PubMed ID: 6293697
[TBL] [Abstract][Full Text] [Related]
17. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats.
Lebrecht D; Geist A; Ketelsen UP; Haberstroh J; Setzer B; Walker UA
Br J Pharmacol; 2007 Jul; 151(6):771-8. PubMed ID: 17519947
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of fresh isolates of soft tissue sarcoma, osteosarcoma and giant cell tumour cells to Apo2L/TRAIL and doxorubicin.
Bouralexis S; Clayer M; Atkins GJ; Labrinidis A; Hay S; Graves S; Findlay DM; Evdokiou A
Int J Oncol; 2004 May; 24(5):1263-70. PubMed ID: 15067350
[TBL] [Abstract][Full Text] [Related]
20. 2-Bromopalmitate sensitizes osteosarcoma cells to adriamycin-induced apoptosis via the modulation of CHOP.
Xu T; Huang C; Qi XT; Yang XC; Zhang N; Cao J; Wang C; Zhu H; Yang B; He QJ; Shao XJ; Ying MD
Eur J Pharmacol; 2019 Feb; 844():204-215. PubMed ID: 30552901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
